Naia Pharmaceuticals Status
The company raised an undisclosed amount of funding from Cedars-Sinai on April 3, 2017.
Operator of a biopharmaceutical company created to develop drugs for Short Bowel Syndrome. The company develops clinically advance drug candidates for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases enabling health care providers to treat gastrointestinal problems and disorders and reduce recovery times.
Startup
Privately Held (backing)
Angel-Backed
The company raised an undisclosed amount of funding from Cedars-Sinai on April 3, 2017.
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review